Education
About Us
Working with TipRanks
Follow Us
Lifeward Ltd. (LFWD)
:LFWD
Top Page
Lifeward
(NASDAQ:LFWD)
Select Model
Select Model
Rating:43Neutral
Price Target:―
Lifeward's stock score is influenced by strong revenue growth but substantial risks due to profitability challenges, negative cash flows, and unattractive valuation. Technical indicators and recent corporate events further underscore the cautious outlook, despite strategic initiatives. Key risks involve financial instability and operational inefficiencies.
Positive Factors
Revenue Growth
Strong revenue growth indicates increasing market demand and successful product adoption, which can drive long-term business expansion and stability.
Strategic Partnerships
Strategic partnerships and market expansion efforts enhance Lifeward's competitive position and open new revenue streams, supporting sustainable growth.
New Product Launches
New product launches and regulatory approvals can drive future sales growth and strengthen market position, enhancing long-term competitiveness.
Negative Factors
Profitability Challenges
Persistent profitability challenges highlight operational inefficiencies, which can hinder financial sustainability and limit growth potential.
Negative Cash Flow
Negative cash flow suggests operational cash deficits, increasing reliance on external funding, which can strain financial health and limit strategic flexibility.
Leadership Changes
Leadership changes can disrupt strategic direction and sales execution, potentially impacting operational stability and long-term growth strategies.
Lifeward (LFWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.39M
Dividend YieldN/A
Average Volume (3M)316.99K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue Growth-2.02%
EPS Growth-32.93%
CountryUS
Employees80
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.19
Shares Outstanding15,704,622
10 Day Avg. Volume318,606
30 Day Avg. Volume316,993
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.80
Price to Sales (P/S)0.59
P/FCF Ratio-0.69
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue0.39
Enterprise Value/Gross Profit1.03
Enterprise Value/Ebitda-0.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lifeward Business Overview & Revenue Model
Company Descriptionnull
How the Company Makes Moneynull
Lifeward Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 19, 2026
Earnings Call Sentiment Neutral
The earnings call for Lifeward Ltd. highlighted significant operational improvements and strategic expansions, particularly in the ReWalk product line and European market access. However, challenges remain with declining revenue in the ATLAS G product line and increased operating expenses. The company is optimistic about its transformation and future growth, bolstered by operational efficiencies and financial backing.Q3-2025 Updates
Positive Updates
Record Quarter for ReWalk Placements
Lifeward Ltd. delivered another record quarter for ReWalk placements for Medicare beneficiaries, marking the second consecutive record since CMS established their fee schedule in April 2024.
Operational Efficiencies Achieved
The company implemented operational efficiencies resulting in a 16% reduction in quarterly cash burn and a 27% reduction in non-GAAP operating loss compared to the previous year.
Expansion into European Market
With CE Mark approval, Lifeward Ltd. expanded access to the European market, representing about 40% of their global addressable exoskeleton opportunity.
Improved Gross Profit Margins
GAAP gross profit was $2.7 million or 43.7% of revenue in 2025, an increase from $2.2 million or 36.2% of revenue in 2024, driven by lower production costs.
$3 Million Loan Agreement
Lifeward Ltd. announced the completion of a $3 million loan with Oramed, enhancing near-term liquidity and supporting ongoing transformation plans.
Negative Updates
Decline in ATLAS G Product Revenue
Revenue from the ATLAS G product and services was $3.1 million in Q3 2025, down from $3.6 million in Q3 2024, primarily due to timing factors and quarterly revenue mix.
Increased GAAP Operating Expenses
GAAP operating expenses increased to $5.9 million in 2025 from $5.4 million in 2024, largely due to a $2 million earn-out write-down recognized in the prior year.
Company Guidance
During the Lifeward Ltd. Third Quarter 2025 Earnings Conference Call, the company provided financial guidance reaffirming full-year 2025 revenue expectations between $24 million and $26 million, and a projected non-GAAP net loss ranging from $12 million to $14 million. The CFO, Almog Adar, highlighted a 16% reduction in quarterly cash burn and a 27% reduction in non-GAAP operating loss compared to the previous year. Revenue for Q3 2025 was $6.2 million, an increase from $6.1 million in 2024, with a notable 24% increase in sales of traditional products like the ReWalk personal exoskeleton. Additionally, Lifeward Ltd. ended the quarter with $2 million in cash, supported by a $3 million loan agreement with Oramed, and anticipates further reductions in operating loss as sales volumes grow.Lifeward Financial Statement Overview
Summary
Lifeward is experiencing strong revenue growth but faces significant profitability challenges. The company has a healthy balance sheet with a high equity ratio, though negative cash flows and earnings pose risks. Future improvements in operational efficiency are crucial for financial sustainability.Income Statement
Lifeward's revenue has shown strong growth, from $4.4 million in 2020 to $25.7 million in 2024, marking a significant upward trajectory. However, the company has consistently posted negative EBIT and net income, indicating operational inefficiencies and challenges in achieving profitability. The gross profit margin is improving but remains offset by high operating expenses.35
Negative
Balance Sheet
The company has a healthy stockholders' equity position, which is significantly higher than its total liabilities, resulting in a low debt-to-equity ratio. However, the return on equity is negative due to consistent net losses, highlighting a risk of financial instability despite the strong equity base.45
Neutral
Cash Flow
Lifeward experiences negative operating and free cash flow, indicating reliance on external financing for operations. The free cash flow growth rate is negative, showing challenges in converting revenue to cash. Cash flow ratios to net income are unfavorable, reflecting operational cash deficits.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.50M | 25.66M | 13.85M | 5.51M | 5.97M | 4.39M |
| Gross Profit | 9.18M | 8.22M | 4.45M | 1.91M | 2.90M | 2.19M |
| EBITDA | -15.91M | -24.93M | -21.77M | -18.90M | -12.39M | -11.73M |
| Net Income | -29.84M | -28.94M | -22.13M | -19.57M | -12.74M | -12.98M |
Balance Sheet | ||||||
| Total Assets | 23.17M | 30.49M | 63.19M | 74.24M | 94.75M | 28.07M |
| Cash, Cash Equivalents and Short-Term Investments | 2.19M | 6.94M | 28.08M | 67.90M | 88.34M | 20.35M |
| Total Debt | 237.00K | 880.00K | 1.90M | 897.00K | 1.06M | 1.58M |
| Total Liabilities | 10.41M | 11.64M | 16.68M | 6.07M | 5.37M | 6.29M |
| Stockholders Equity | 12.76M | 18.85M | 46.51M | 68.17M | 89.38M | 21.77M |
Cash Flow | ||||||
| Free Cash Flow | -17.25M | -21.72M | -20.75M | -17.92M | -11.52M | -12.66M |
| Operating Cash Flow | -17.24M | -21.72M | -20.67M | -17.89M | -11.47M | -12.59M |
| Investing Cash Flow | -5.00K | 0.00 | -18.15M | -25.00K | -47.00K | -73.00K |
| Financing Cash Flow | 8.43M | 0.00 | -992.00K | -2.50M | 79.51M | 16.72M |
Lifeward Technical Analysis
Neutral
0.70
Price Trends
0.65
Negative
0.66
Negative
1.04
Negative
Market Momentum
-0.03
Negative
47.80
Neutral
22.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFWD, the sentiment is Neutral. The current price of 0.7 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.65, and below the 200-day MA of 1.04, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.80 is Neutral, neither overbought nor oversold. The STOCH value of 22.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LFWD.
Lifeward Risk Analysis
Lifeward disclosed 62 risk factors in its most recent earnings report. Lifeward reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
Lifeward Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $10.04M | 0.32 | 20.03% | ― | -99.28% | -46.16% | |
43 Neutral | $9.39M | ― | -127.95% | ― | -2.02% | -32.93% | |
41 Neutral | $20.32M | -0.35 | -62.12% | ― | -87.84% | 29.16% | |
41 Neutral | $14.76M | -0.16 | -179.63% | ― | 147.74% | 73.23% | |
38 Underperform | $7.12M | -1.62 | -69.61% | ― | -11.31% | 47.64% | |
38 Underperform | $3.49M | -0.28 | ― | ― | ― | ― |
* Healthcare Sector Average
LFWD
Lifeward
0.58
-1.48
-71.80%
BMRA
Biomerica
2.29
-0.13
-5.37%
CODX
Co-Diagnostics
0.33
-0.60
-64.52%
XAIR
Beyond Air
1.28
-12.06
-90.40%
PAVM
PAVmed
0.32
-0.58
-64.11%
DHAI
DIH Holdings US, Inc Class A
0.03
-26.97
-99.89%
Lifeward Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Lifeward Announces Termination of Chief Sales Officer
Negative
Apr 14, 2025
Lifeward has announced that Charles Remsberg’s role as Chief Sales Officer will be terminated without cause, effective May 30, 2025. This decision, disclosed in the company’s annual report, ensures Mr. Remsberg will receive severance and benefits as per his employment agreement, potentially impacting the company’s sales leadership and strategy.
Spark’s Take on LFWD Stock
According to Spark, TipRanks’ AI Analyst, LFWD is a Neutral.
Lifeward’s stock is rated low primarily due to ongoing financial challenges, despite strong revenue growth. Technical indicators suggest a current downtrend, and valuation metrics are unattractive due to negative earnings. While strategic initiatives show promise, the high risks associated with financial instability and operational inefficiencies are significant concerns.
To see Spark’s full report on LFWD stock, click here.
Executive/Board Changes
Rewalk Robotics CEO Larry Jasinski to Step Down
Neutral
Feb 20, 2025
On February 19, 2025, Rewalk Robotics announced that Larry Jasinski will step down as CEO and board member by the end of the second quarter of 2025. Jasinski’s departure will be considered a termination without cause, and the company plans to finalize a separation agreement with him before his exit.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.